← BLACKLEDGER Content Feed

Selling • NEUROPHAGE x BLACKLEDGER • 8 min read • 2026-07-25

BLACKLEDGER Selling Watch: DNN, CRSP, SOFI

BLACKLEDGERMarket ResearchSellingDNNCRSPSOFIAVAX
BLACKLEDGER Selling public market research update for DNN, CRSP, SOFI

BLACKLEDGER's latest selling watch update tracks DNN, CRSP, SOFI, AVAX, SOL, ABOS from the active public watchlist. This post is built from public-safe status data, in-house public signal labels, and outside public source context. It is designed to help readers understand what is happening around each asset without exposing private research methods.

Selling Watch Data

The dedicated feed category for this update is Selling. The latest public scan timestamp is 2026-07-25T08:00:41.396030+00:00.

Educational Context: How To Use This Page

This page is not a trade instruction. It is an educational research brief. Readers can use it to understand company or project background, public market context, public status labels, and relevant outside-source headlines before doing their own due diligence.

DNN Public Research Bio

Name: Denison Mines Corp.. Market class: stock. Public bias: Bear. Public tier: Extended.

Denison Mines Corp. engages in the acquisition, exploration, and development of uranium bearing properties in Canada. It holds 95% interest in its flagship project Wheeler River uranium project located in the Athabasca Basin region in northern Saskatchewan. The company was formerly known as International Uranium Corporation and changed its name to Denison Mines Corp. in December 2006. The company was founded in 1954 and is headquartered in Toronto, Canada.

Why DNN Is In This Public Update

Outside Public Headlines / Source Notes

CRSP Public Research Bio

Name: CRISPR Therapeutics AG. Market class: stock. Public bias: Bear. Public tier: Extended.

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemog

Why CRSP Is In This Public Update

Outside Public Headlines / Source Notes

SOFI Public Research Bio

Name: SoFi Technologies, Inc.. Market class: stock. Public bias: Bear. Public tier: Extended.

SoFi Technologies, Inc. provides various financial services in the United States, Latin America, Canada, and Hong Kong. The company operates through three segments: Lending, Technology Platform, and Financial Services. It offers lending and financial services and products that allows its members to borrow, save, spend, invest, and protect money; and personal loans, student loans, home loans, and related services. The company also operates Galileo, a technology platform that offers services to financial and non-financial institution; and Technisys, a cloud-native digital and core banking platform that provides software licenses and associated services, including implementation and maintenance. In addition, it provides SoFi Money offers checking and savings accounts, and cash management products; SoFi Invest, a mobile-first investment platform that offers access to trading and advisory solutions, such as investing and robo-advisory; and S

Why SOFI Is In This Public Update

Outside Public Headlines / Source Notes

AVAX Public Research Bio

Name: Avalanche USD. Market class: crypto. Public bias: Bear. Public tier: Extended.

Avalanche (AVAX) is a cryptocurrency launched in 2020. Avalanche has a current supply of 463,441,061.1772119 with 431,771,961.1772119 in circulation. The last known price of Avalanche is 6.19744931 USD and is down -4.08 over the last 24 hours. It is currently trading on 1100 active market(s) with $268,552,202.67 traded over the last 24 hours. More information can be found at https://avax.network/.

Why AVAX Is In This Public Update

Outside Public Headlines / Source Notes

SOL Public Research Bio

Name: Solana USD. Market class: crypto. Public bias: Bear. Public tier: Extended.

Solana (SOL) is a cryptocurrency launched in 2020. Solana has a current supply of 630,867,471.17279017 with 582,864,816.14035106 in circulation. The last known price of Solana is 74.41939808 USD and is down -3.07 over the last 24 hours. It is currently trading on 1147 active market(s) with $1,576,911,918.67 traded over the last 24 hours. More information can be found at https://solana.com.

Why SOL Is In This Public Update

Outside Public Headlines / Source Notes

ABOS Public Research Bio

Deep bio flag: This asset reached the 9+ public rating threshold, so BLACKLEDGER includes a fuller company/project profile, outside-source context, and public education notes.

Name: Acumen Pharmaceuticals, Inc.. Market class: stock. Public bias: Bear. Public tier: Extended.

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.

Why ABOS Is In This Public Update

Outside Public Headlines / Source Notes

What The Public Data Shows

The public feed highlights ticker status, market class, directional bias, score, tier, confidence, company or project profile, public market references, and outside-source headlines. These fields support a deeper view of BLACKLEDGER's public research feed while keeping private methods undisclosed.

Why This Category Matters

The Selling section gives readers a focused path through the market: buying watch content for constructive candidates, selling watch content for defensive movement, investing content for higher-quality public watch names, and market trend notes for broader context.

Research-Only Notice

BLACKLEDGER content is market research only. There is no live execution signal, no recommendation to buy or sell, and no financial advice. Readers should perform their own due diligence and consult licensed professionals before making financial decisions.

Research-only. No execution signal. Not financial advice.